Featured Posters & Presentations
Lyfgenia
Interim results from a phase 1/2 clinical study of LentiGlobin gene therapy for severe sickle cell disease.
Authors: Kanter J.
Zynteglo
LentiGlobin gene therapy for transfusion-dependent β-thalassemia: update from the Northstar Hgb-204 phase 1/2 clinical study.
Authors: Thompson AA.